Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.57 | N/A | -43.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.57 | N/A | -43.94% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding current market conditions. They highlighted their commitment to innovation and long-term strategies.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term growth despite short-term setbacks.
The earnings report shows that 10X Genomics faced challenges, particularly reflected in the EPS miss. However, the stock rose by 2.04%, indicating that investors may be optimistic about the company's long-term potential despite the current difficulties. Management's focus on innovation suggests they are positioning for future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BROOKFIELD RENEW PAR
Aug 5, 2022